MOR Stock Overview
MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
MorphoSys AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €18.04 |
52 Week High | €18.31 |
52 Week Low | €4.19 |
Beta | 0.60 |
1 Month Change | -0.61% |
3 Month Change | 82.78% |
1 Year Change | 249.61% |
3 Year Change | -22.38% |
5 Year Change | -25.88% |
Change since IPO | -30.13% |
Recent News & Updates
Novartis And MorphoSys Are A Perfect Match
Feb 06MorphoSys: Positive Pelabresib Data Finally Unlocking Upside
Jan 18Recent updates
Novartis And MorphoSys Are A Perfect Match
Feb 06MorphoSys: Positive Pelabresib Data Finally Unlocking Upside
Jan 18MorphoSys updates Q2 & FY22 guidance below prior provided levels
Jul 26MorphoSys May Not Recover From Adventurous Constellation Buyout
May 04Sierra Oncology's Strong Data In Myelofibrosis Challenges MorphoSys And Incyte
Jan 28Incyte and MorphoSys presents new three-year data for blood cancer therapy
Jun 04MorphoSys reports Q1 results
May 05MorphoSys AG appoints Sangamo 's Sung Lee as new CFO
Jan 06MorphoSys AG (MOR) Investor Presentation - Slideshow
Dec 08MorphoSys AG 2020 Q3 - Results - Earnings Call Presentation
Nov 22MorphoSys reports Q3 results
Nov 11Shareholder Returns
MOR | US Biotechs | US Market | |
---|---|---|---|
7D | 0% | 1.5% | 1.2% |
1Y | 249.6% | 1.1% | 24.7% |
Return vs Industry: MOR exceeded the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: MOR exceeded the US Market which returned 24.7% over the past year.
Price Volatility
MOR volatility | |
---|---|
MOR Average Weekly Movement | 17.0% |
Biotechs Industry Average Movement | 11.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MOR's share price has been volatile over the past 3 months.
Volatility Over Time: MOR's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1992 | 524 | Jean-Paul Kress | www.morphosys.com |
MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company’s product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren’s disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis.
MorphoSys AG Fundamentals Summary
MOR fundamental statistics | |
---|---|
Market cap | US$2.73b |
Earnings (TTM) | -US$203.10m |
Revenue (TTM) | US$255.06m |
10.7x
P/S Ratio-13.4x
P/E RatioIs MOR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MOR income statement (TTM) | |
---|---|
Revenue | €238.28m |
Cost of Revenue | €58.35m |
Gross Profit | €179.92m |
Other Expenses | €369.66m |
Earnings | -€189.73m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 29, 2024
Earnings per share (EPS) | -5.04 |
Gross Margin | 75.51% |
Net Profit Margin | -79.63% |
Debt/Equity Ratio | 3,428.8% |
How did MOR perform over the long term?
See historical performance and comparison